Table 1.
Description of total and specific G to A mutations identified in HIV-1 provirus from infected cells exposed to different treatments.
| Treatment | Donor ID | Number of mutations respect to Ba-L | Number of G → A mutations respect to Ba-L |
|---|---|---|---|
| None | dn01 | 2 | 1 |
| dn02 | 1 | 0 | |
| dn03 | 0 | 0 | |
| dn04 | 0 | 0 | |
| Mean | 0.75 ± 0.96 | 0.25 ± 0.50 | |
| Vasoactive intestinal peptide | dn01 | 4 | 0 |
| dn02 | 3 | 0 | |
| dn03 | 4 | 1 | |
| dn04 | 2 | 1 | |
| Mean | 3.25 ± 0.96 | 0.50 ± 0.58 | |
| Pituitary adenylate cyclase-activating polypeptide | dn01 | 8 | 2 |
| dn02 | 13 | 4 | |
| dn03 | 5 | 1 | |
| dn04 | 4 | 1 | |
| Mean | 7.50 ± 4.04 | 2.00 ± 1.41 | |
| INFα | dn01 | 7 | 5 |
| dn02 | 8 | 3 | |
| dn03 | 4 | 1 | |
| dn04 | 5 | 1 | |
| Mean | 6.00 ± 1.83 | 2.50 ± 1.92 | |